|
|
- April 3, 2012
Search for New Analgesics Worth the Pain Given Side Effects of Opioids
- February 9, 2012
Zalicus and Hydra Collaborate to Advance Novel Ion Channel Product Candidates for the Treatment of Pain
- January 10, 2012
Cubist and Hydra Announce Plans to Initiate Phase 1 Clinical Trial
- August 1, 2011
Transient receptor potential channels as therapeutic targets
- November 11, 2010
TRPping up overactive bladder
- November 10, 2010
TRPA1 Contributes to Cold Hypersensitivity
- October 20, 2010
Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis
- October 19, 2009
Hydra Biosciences and Cubist Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management
- May 18, 2009
Research published in PNAS by Hydra Biosciences is First Demonstration in Mammals that TRP Ion Channel Drug Can Treat Allergy-Induced Asthma
- January 20, 2009
Emerging Drug Developer: Hydra Biosciences (FierceBiotech)
- January 16, 2009
Hydra Brings in $22M in Series D to Push First Program into Clinic (BioWorld Today)
- January 16, 2009
Hydra Biosciences Reaps $22.2M Series D (Dow Jones VentureWire)
- January 16, 2009
Hydra Biosciences Raises $22M to Create New Pain Relievers With Fewer Side Effects (Xconomy)
- January 16, 2009
Hydra garners $22M for ion channel programs (FierceBiotech)
- January 16, 2009
Hydra Biosciences Raises $22 Million in Series D Financing
- October 24, 2008
Hydra Biosciences Bolsters Discovery and IP Capabilities with Key Additions to Executive Management Team
- January 2, 2008
Hydra Biosciences CEO Russell Herndon Interviewed on NECN (QuickTime movie, 7 MB)
- November 16, 2007
Hydra Biosciences Featured in Mass High Tech Article
- August 14, 2007
Hydra Biosciences Publishes Article in PNAS Demonstrating that TRPA1 Mediates Formalin-Induced Pain
- August 7, 2007
Hydra Biosciences Announces Data Revealing the Crucial Role Played by the TRPA1 Ion Channel in a Standard Model of Pain Receptor Activation
- July 26, 2007
Hydra Biosciences and Pfizer Global Research & Development Sign Collaboration Agreement
- April 25, 2006
Hydra Biosciences Co-founder Dr. David Clapham Elected to the National Academy of Sciences
- January 5, 2006
Hydra Biosciences Appoints Russell H. Herndon as Chief Executive Officer
- April 1, 2005
Sophion and Hydra Establish a Unique Reference Site for QPatch Automated Patch Clamp System
- April 26, 2004
Hydra Biosciences Co-founder Dr. Mark Keating Elected to the National Academy of Sciences
- January 12, 2004
Hydra Biosciences Raises $18.875 Million in Series B Financing
|
